Veru (NASDAQ:VERU) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Veru (NASDAQ:VERU) from a hold rating to a sell rating in a research note issued to investors on Saturday.

A number of other equities research analysts also recently weighed in on VERU. Oppenheimer reissued an “outperform” rating on shares of Veru in a report on Thursday, December 18th. Canaccord Genuity Group started coverage on shares of Veru in a research note on Thursday, December 18th. They set a “buy” rating and a $25.00 target price for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Veru in a report on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Veru has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Veru Stock Performance

Shares of NASDAQ VERU opened at $2.57 on Friday. Veru has a 1 year low of $2.10 and a 1 year high of $7.40. The firm has a market cap of $41.25 million, a P/E ratio of -1.17 and a beta of -1.42. The stock has a fifty day moving average price of $2.43 and a two-hundred day moving average price of $3.25.

Veru (NASDAQ:VERU) last posted its quarterly earnings data on Wednesday, December 17th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.18. During the same period in the prior year, the company posted ($0.28) earnings per share. On average, research analysts predict that Veru will post -0.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Veru

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Blair William & Co. IL boosted its holdings in shares of Veru by 8.6% during the second quarter. Blair William & Co. IL now owns 380,000 shares of the company’s stock worth $221,000 after purchasing an additional 30,000 shares during the period. 180 Wealth Advisors LLC lifted its position in Veru by 5.9% in the 2nd quarter. 180 Wealth Advisors LLC now owns 458,887 shares of the company’s stock worth $267,000 after buying an additional 25,554 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Veru during the 2nd quarter valued at $90,000. Atria Investments Inc boosted its stake in shares of Veru by 11.5% during the 2nd quarter. Atria Investments Inc now owns 282,281 shares of the company’s stock valued at $164,000 after buying an additional 29,025 shares during the period. Finally, Allworth Financial LP purchased a new position in shares of Veru during the 2nd quarter valued at $45,000. Institutional investors and hedge funds own 47.16% of the company’s stock.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.